Zobrazeno 1 - 2
of 2
pro vyhledávání: '"Biernat MC"'
Autor:
Corboz MR; Insmed Incorporated, Research & Development, Bridgewater, New Jersey (M.R.C., Z.L., V.M., A.J.P., D.M.K., F.G.L., K.-J.C., W.R.P., R.W.C.); IPS Therapeutique Inc., Sherbrooke, Québec, Canada (C.E.L., H.Y., M.C.B., D.S.); Lovelace Respiratory Research Institute, Pathophysiology Program, Albuquerque, New Mexico (J.Z., F.X.); and Envigo CRS Inc., East Millstone, New Jersey (A.C.) michel.corboz@insmed.com., Li Z; Insmed Incorporated, Research & Development, Bridgewater, New Jersey (M.R.C., Z.L., V.M., A.J.P., D.M.K., F.G.L., K.-J.C., W.R.P., R.W.C.); IPS Therapeutique Inc., Sherbrooke, Québec, Canada (C.E.L., H.Y., M.C.B., D.S.); Lovelace Respiratory Research Institute, Pathophysiology Program, Albuquerque, New Mexico (J.Z., F.X.); and Envigo CRS Inc., East Millstone, New Jersey (A.C.)., Malinin V; Insmed Incorporated, Research & Development, Bridgewater, New Jersey (M.R.C., Z.L., V.M., A.J.P., D.M.K., F.G.L., K.-J.C., W.R.P., R.W.C.); IPS Therapeutique Inc., Sherbrooke, Québec, Canada (C.E.L., H.Y., M.C.B., D.S.); Lovelace Respiratory Research Institute, Pathophysiology Program, Albuquerque, New Mexico (J.Z., F.X.); and Envigo CRS Inc., East Millstone, New Jersey (A.C.)., Plaunt AJ; Insmed Incorporated, Research & Development, Bridgewater, New Jersey (M.R.C., Z.L., V.M., A.J.P., D.M.K., F.G.L., K.-J.C., W.R.P., R.W.C.); IPS Therapeutique Inc., Sherbrooke, Québec, Canada (C.E.L., H.Y., M.C.B., D.S.); Lovelace Respiratory Research Institute, Pathophysiology Program, Albuquerque, New Mexico (J.Z., F.X.); and Envigo CRS Inc., East Millstone, New Jersey (A.C.)., Konicek DM; Insmed Incorporated, Research & Development, Bridgewater, New Jersey (M.R.C., Z.L., V.M., A.J.P., D.M.K., F.G.L., K.-J.C., W.R.P., R.W.C.); IPS Therapeutique Inc., Sherbrooke, Québec, Canada (C.E.L., H.Y., M.C.B., D.S.); Lovelace Respiratory Research Institute, Pathophysiology Program, Albuquerque, New Mexico (J.Z., F.X.); and Envigo CRS Inc., East Millstone, New Jersey (A.C.)., Leifer FG; Insmed Incorporated, Research & Development, Bridgewater, New Jersey (M.R.C., Z.L., V.M., A.J.P., D.M.K., F.G.L., K.-J.C., W.R.P., R.W.C.); IPS Therapeutique Inc., Sherbrooke, Québec, Canada (C.E.L., H.Y., M.C.B., D.S.); Lovelace Respiratory Research Institute, Pathophysiology Program, Albuquerque, New Mexico (J.Z., F.X.); and Envigo CRS Inc., East Millstone, New Jersey (A.C.)., Chen KJ; Insmed Incorporated, Research & Development, Bridgewater, New Jersey (M.R.C., Z.L., V.M., A.J.P., D.M.K., F.G.L., K.-J.C., W.R.P., R.W.C.); IPS Therapeutique Inc., Sherbrooke, Québec, Canada (C.E.L., H.Y., M.C.B., D.S.); Lovelace Respiratory Research Institute, Pathophysiology Program, Albuquerque, New Mexico (J.Z., F.X.); and Envigo CRS Inc., East Millstone, New Jersey (A.C.)., Laurent CE; Insmed Incorporated, Research & Development, Bridgewater, New Jersey (M.R.C., Z.L., V.M., A.J.P., D.M.K., F.G.L., K.-J.C., W.R.P., R.W.C.); IPS Therapeutique Inc., Sherbrooke, Québec, Canada (C.E.L., H.Y., M.C.B., D.S.); Lovelace Respiratory Research Institute, Pathophysiology Program, Albuquerque, New Mexico (J.Z., F.X.); and Envigo CRS Inc., East Millstone, New Jersey (A.C.)., Yin H; Insmed Incorporated, Research & Development, Bridgewater, New Jersey (M.R.C., Z.L., V.M., A.J.P., D.M.K., F.G.L., K.-J.C., W.R.P., R.W.C.); IPS Therapeutique Inc., Sherbrooke, Québec, Canada (C.E.L., H.Y., M.C.B., D.S.); Lovelace Respiratory Research Institute, Pathophysiology Program, Albuquerque, New Mexico (J.Z., F.X.); and Envigo CRS Inc., East Millstone, New Jersey (A.C.)., Biernat MC; Insmed Incorporated, Research & Development, Bridgewater, New Jersey (M.R.C., Z.L., V.M., A.J.P., D.M.K., F.G.L., K.-J.C., W.R.P., R.W.C.); IPS Therapeutique Inc., Sherbrooke, Québec, Canada (C.E.L., H.Y., M.C.B., D.S.); Lovelace Respiratory Research Institute, Pathophysiology Program, Albuquerque, New Mexico (J.Z., F.X.); and Envigo CRS Inc., East Millstone, New Jersey (A.C.)., Salvail D; Insmed Incorporated, Research & Development, Bridgewater, New Jersey (M.R.C., Z.L., V.M., A.J.P., D.M.K., F.G.L., K.-J.C., W.R.P., R.W.C.); IPS Therapeutique Inc., Sherbrooke, Québec, Canada (C.E.L., H.Y., M.C.B., D.S.); Lovelace Respiratory Research Institute, Pathophysiology Program, Albuquerque, New Mexico (J.Z., F.X.); and Envigo CRS Inc., East Millstone, New Jersey (A.C.)., Zhuang J; Insmed Incorporated, Research & Development, Bridgewater, New Jersey (M.R.C., Z.L., V.M., A.J.P., D.M.K., F.G.L., K.-J.C., W.R.P., R.W.C.); IPS Therapeutique Inc., Sherbrooke, Québec, Canada (C.E.L., H.Y., M.C.B., D.S.); Lovelace Respiratory Research Institute, Pathophysiology Program, Albuquerque, New Mexico (J.Z., F.X.); and Envigo CRS Inc., East Millstone, New Jersey (A.C.)., Xu F; Insmed Incorporated, Research & Development, Bridgewater, New Jersey (M.R.C., Z.L., V.M., A.J.P., D.M.K., F.G.L., K.-J.C., W.R.P., R.W.C.); IPS Therapeutique Inc., Sherbrooke, Québec, Canada (C.E.L., H.Y., M.C.B., D.S.); Lovelace Respiratory Research Institute, Pathophysiology Program, Albuquerque, New Mexico (J.Z., F.X.); and Envigo CRS Inc., East Millstone, New Jersey (A.C.)., Curran A; Insmed Incorporated, Research & Development, Bridgewater, New Jersey (M.R.C., Z.L., V.M., A.J.P., D.M.K., F.G.L., K.-J.C., W.R.P., R.W.C.); IPS Therapeutique Inc., Sherbrooke, Québec, Canada (C.E.L., H.Y., M.C.B., D.S.); Lovelace Respiratory Research Institute, Pathophysiology Program, Albuquerque, New Mexico (J.Z., F.X.); and Envigo CRS Inc., East Millstone, New Jersey (A.C.)., Perkins WR; Insmed Incorporated, Research & Development, Bridgewater, New Jersey (M.R.C., Z.L., V.M., A.J.P., D.M.K., F.G.L., K.-J.C., W.R.P., R.W.C.); IPS Therapeutique Inc., Sherbrooke, Québec, Canada (C.E.L., H.Y., M.C.B., D.S.); Lovelace Respiratory Research Institute, Pathophysiology Program, Albuquerque, New Mexico (J.Z., F.X.); and Envigo CRS Inc., East Millstone, New Jersey (A.C.)., Chapman RW; Insmed Incorporated, Research & Development, Bridgewater, New Jersey (M.R.C., Z.L., V.M., A.J.P., D.M.K., F.G.L., K.-J.C., W.R.P., R.W.C.); IPS Therapeutique Inc., Sherbrooke, Québec, Canada (C.E.L., H.Y., M.C.B., D.S.); Lovelace Respiratory Research Institute, Pathophysiology Program, Albuquerque, New Mexico (J.Z., F.X.); and Envigo CRS Inc., East Millstone, New Jersey (A.C.).
Publikováno v:
The Journal of pharmacology and experimental therapeutics [J Pharmacol Exp Ther] 2017 Dec; Vol. 363 (3), pp. 348-357. Date of Electronic Publication: 2017 Sep 13.
Publikováno v:
Circulation Research; 4/29/2022, Vol. 130 Issue 9, p1404-1422, 19p